Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients

被引:259
作者
Elmaagacli, Ahmet H. [1 ]
Steckel, Nina K. [1 ]
Koldehoff, Michael [1 ]
Hegerfeldt, Yael [1 ]
Trenschel, Rudolf [1 ]
Ditschkowski, Markus [1 ]
Christoph, Sandra [1 ]
Gromke, Tanja [1 ]
Kordelas, Lambros [1 ]
Ottinger, Hellmut D. [1 ]
Ross, Rudolf S. [2 ]
Horn, Peter A. [3 ]
Schnittger, Susanne [4 ]
Beelen, Dietrich W. [1 ]
机构
[1] Univ Duisburg Essen, Dept Bone Marrow Transplantat, W German Canc Ctr, Univ Hosp Essen, D-45122 Essen, Germany
[2] Univ Duisburg Essen, Inst Virol, Univ Hosp Essen, D-45122 Essen, Germany
[3] Univ Duisburg Essen, Inst Transfus Med, Univ Hosp Essen, D-45122 Essen, Germany
[4] Munich Leukemia Lab, Munich, Germany
关键词
STEM-CELL TRANSPLANTATION; BONE-MARROW; HOST-DISEASE; PP65; ANTIGENEMIA; REDUCED RISK; T-CELLS; CMV; RECIPIENTS; DONORS; RECONSTITUTION;
D O I
10.1182/blood-2010-08-304121
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The impact of early human cytomegalovirus (HCMV) replication on leukemic recurrence was evaluated in 266 consecutive adult (median age, 47 years; range, 18-73 years) acute myeloid leukemia patients, who underwent allogeneic stem cell transplantation (alloSCT) from 10 of 10 high-resolution human leukocyte Ag-identical unrelated (n = 148) or sibling (n = 118) donors. A total of 63% of patients (n = 167) were at risk for HCMV reactivation by patient and donor pretransplantation HCMV serostatus. In 77 patients, first HCMV replication as detected by pp65-antigenemia assay developed at a median of 46 days (range, 25-108 days) after alloSCT. Taking all relevant competing risk factors into account, the cumulative incidence of hematologic relapse at 10 years after alloSCT was 42% (95% confidence interval [CI], 35%-51%) in patients without opposed to 9% (95% CI, 4%-19%) in patients with early pp65-antigenemia (P < .0001). A substantial and independent reduction of the relapse risk associated with early HCMV replication was confirmed by multivariate analysis using time-dependent covariate functions for grades II to IV acute and chronic graft-versus-host disease, and pp65-antigenemia (hazard ratio = 0.2; 95% CI, 0.1-0.4, P < .0001). This is the first report that demonstrates an independent and substantial reduction of the leukemic relapse risk after early replicative HCMV infection in a homogeneous population of adult acute myeloid leukemia patients. (Blood. 2011; 118(5): 1402-1412)
引用
收藏
页码:1402 / 1412
页数:11
相关论文
共 35 条
[1]   Influence of intestinal bacterial decontamination using metronidazole and ciprofloxacin or ciprofloxacin alone on the development of acute graft-versus-host disease after marrow transplantation in patients with hematologic malignancies:: Final results and long-term follow-up of an open-label prospective randomized trial [J].
Beelen, DW ;
Elmaagacli, A ;
Müller, KD ;
Hirche, H ;
Schaefer, UW .
BLOOD, 1999, 93 (10) :3267-3275
[2]   6 WEEKS OF CONTINUOUS INTRAVENOUS CYCLOSPORINE AND SHORT-COURSE METHOTREXATE AS PROPHYLAXIS FOR ACUTE GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION [J].
BEELEN, DW ;
QUABECK, K ;
KAISER, B ;
WIEFELSPUTZ, J ;
SCHEULEN, ME ;
GRAEVEN, U ;
GROSSEWILDE, H ;
SAYER, HG ;
SCHAEFER, UW .
TRANSPLANTATION, 1990, 50 (03) :421-427
[3]   Donor and Recipient CMV Serostatus and Outcome of Pediatric Allogeneic HSCT for Acute Leukemia in the Era of CMV-Preemptive Therapy [J].
Behrendt, Carolyn E. ;
Rosenthal, Joseph ;
Bolotin, Ellen ;
Nakamura, Ryotaro ;
Zaia, John ;
Forman, Stephen J. .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2009, 15 (01) :54-60
[4]   The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy [J].
Boeckh, M ;
Nichols, WG .
BLOOD, 2004, 103 (06) :2003-2008
[5]   Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies [J].
Boeckh, M ;
Nichols, WG ;
Papanicolaou, G ;
Rubin, R ;
Wingard, JR ;
Zaia, Y .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2003, 9 (09) :543-558
[6]   Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: A randomized double-blind study [J].
Boeckh, M ;
Gooley, TA ;
Myerson, D ;
Cunningham, T ;
Schoch, G ;
Bowden, RA .
BLOOD, 1996, 88 (10) :4063-4071
[7]  
Boeckh Michael, 2003, Herpes, V10, P12
[8]   Prospective Cytomegalovirus Monitoring During First-Line Chemotherapy in Patients With Acute Myeloid Leukemia [J].
Capria, Saveria ;
Gentile, Giuseppe ;
Capobianchi, Angela ;
Cardarelli, Luisa ;
Gianfelici, Valentina ;
Trisolini, Silvia Maria ;
Foa, Robin ;
Martino, Pietro ;
Meloni, Giovanni .
JOURNAL OF MEDICAL VIROLOGY, 2010, 82 (07) :1201-1207
[9]   Prediction of cumulative incidence function under the proportional hazards model [J].
Cheng, SC ;
Fine, JP ;
Wei, LJ .
BIOMETRICS, 1998, 54 (01) :219-228
[10]  
COX DR, 1972, J R STAT SOC B, V34, P187